Notícias

Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 0.3% and the

Oral Wegovy is now cleared in all EU member states.

Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.4% and the State

Novo Nordisk (NVO) said Wednesday the European Commission granted marketing authorization for Wegovy

Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.

European equities traded in the US as American depositary receipts were rising on Wednesday morning,

UBS has told clients the recent sell-off in artificial intelligence stocks looks inconsistent with the fundamentals and has pushed AI themes back to the top of its rankings. The bank's 'Theme-ometer', a quantitative framework that scores investment themes across macro conditions, earnings,...

Microsoft Corporation (NASDAQ:MSFT) is one of the high-growth wide-moat stocks to buy. On July 2, Microsoft launched Microsoft Frontier Company with $2.5 billion in funding to help large customers deploy AI systems around their own data and workflows. Reuters reported that the unit will begin by working with clients including Unilever and Novo Nordisk and […]

The company’s second upgrade to annual guidance is a sign that companies are scrambling for its semiconductor-making tools in the race to build AI infrastructure.

Don't wait until clinical milestones send their share prices soaring.

Since its obesity pill Foundayo hit the market in April, Lilly has captured about 11% of the prescription volume for new pills, according to the latest weekly data. Novo Nordisk’s Wegovy pill, which launched in January, commands the rest. It is a remarkable turn of events for the near $80 billion anti-obesity market, among the hottest in the industry.

Novo Nordisk presented long-term phase 3 data for denecimig (Mim8) prophylaxis in hemophilia patients, showing sustained efficacy, safety, and treatment satisfaction. The company also reported first efficacy and safety results for concizumab (Alhemo) in pediatric hemophilia patients under 12, indicating reduced bleeding and manageable safety. These trial readouts expand evidence across both adult and pediatric populations, supporting Novo Nordisk’s position in rare blood disorders. For...

Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.

NPM-139 is a miniature subdermal implant that delivers medication steadily over periods of time.

Vivani says its implant delivers medication steadily over long periods of time.

Eyes are on the rollout of Lilly's new weight loss pill.

Eli Lilly has whipsawed shareholders in 2026, but one under-the-radar catalyst in its pipeline could change the trajectory entirely. Here is what the bulls are watching that most investors are still sleeping on.

This is the list for you if you are looking for dividend stocks with attractive yields and well-supported dividends.

So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.

Novo Nordisk stock gains 11% in a month as Wegovy access expands and U.K. approval boosts optimism, but rising competition and earnings pressure cloud the outlook.

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

An accelerated approval for Agios' key drug to treat sickle cell disease appears to be on the cards.

Eli Lilly makes the best-selling GLP-1 drug, and sales are accelerating.

Novo Nordisk (NYSE:NVO) is back in focus after Singapore regulators updated the label for Wegovy’s semaglutide with data from the STEP UP obesity trial, giving investors fresh detail on efficacy for patients without diabetes. See our latest analysis for Novo Nordisk. The updated Wegovy data lands against a mixed backdrop for Novo Nordisk’s stock, with the share price up 19.19% over 30 days and 30.58% over 90 days, yet the 1 year total shareholder return is down 27.53% and the 3 year total...

Novo Nordisk (NYSE:NVO) has updated the Wegovy label in Singapore to include new STEP UP trial data for adults with obesity. The label change reflects clinically meaningful benefits observed in the STEP UP study for semaglutide in obesity treatment. The update comes as obesity drug developers draw fresh attention from investors, including renewed buyout speculation around peers such as Viking Therapeutics. Novo Nordisk, trading at $48.89, sits at the center of renewed interest in obesity...

The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is the default healthcare allocation for millions of investors, and for good reason. XLV owns the entire S&P 500 healthcare complex in one ticker: insurers, device makers, biotech, and Big Pharma. It has returned 21.61% over the past year and 159.84% over ten years. If the reason ... Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%

Vivani Medical’s new agreement gives Novo Nordisk (CPSE:NOVO B) access to evaluate NPM-139, a semaglutide implant for chronic weight management, offering investors another data point on the company’s obesity drug delivery options. See our latest analysis for Novo Nordisk. The Vivani agreement lands at a time when Novo Nordisk’s DKK323.15 share price has shown strong short term momentum, with a 30 day share price return of 18.81% and a 90 day share price return of 35.72%. Over longer periods,...

Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen finances and its neurodegenerative pipeline continues to expand.

Viking Therapeutics' expanding obesity pipeline and upcoming VK2735 data reignite buyout speculation as investors weigh its growing strategic appeal.

The GLP-1 trade has matured from a single-stock story into a tiered opportunity set. Demand for obesity therapeutics keeps expanding as lower-cost, easier-to-administer oral pill versions of the current injectable GLP-1s are introduced to the market in 2026, and the field now spans an entrenched leader, a deep-value incumbent, and a clinical-stage challenger with multiple ... 3 High Growth GLP-1 Biotech Winners to Buy in July